Kornimate/medical-research-clean huggingface dataset:
renin levels as prognostic indicators of septic shock severity and outcome

Conditions: Sepsis; Septic Shock

Summary: the surviving sepsis campaign (ssc) of 2021 characterizes sepsis as a life-threatening organ dysfunction caused by a dysregulated host response to infection, with a mortality rate of over 30%, which increases to 40% or more in the case of septic shock. although concept of sepsis has improved, significant gaps remain in assessing its clinical severity and predicting patient outcomes. recognized markers of the severity of septic shock are procalcitonin (pct), presepsin, and, to a certain extent, lactate. elevated lactate levels result from a shift to anaerobic glycolysis and indicate inadequate oxygen delivery to tissues. despite the importance of procalcitonin in the course of sepsis, it has proven to be a suboptimal diagnostic biomarker for the development of sepsis, with sensitivity and specificity below 80%. as a result, the use of procalcitonin in addition to clinical assessment to determine the indications for initiating antibiotic therapy is not recommended. meanwhile, presepsin, although a potential biomarker for the early diagnosis of sepsis, also has only moderate accuracy according to current data and cannot be used as the only test for the diagnosis of sepsis. renin is a crucial enzyme in the renin-angiotensin-aldosterone system (raas), which plays an important role in the regulation of blood pressure, tissue perfusion, and the balance of water and electrolytes. thus, renin may be the sensitive biomarker with good prognostic qualities in the context of sepsis and septic shock. preliminary studies have indicated that elevated renin levels may act as an indicator of patient severity, and could also be used as a marker for the development of septic shock and mortality prognosis. this study aims to address these gaps by investigating the role of renin as a biomarker for the severity of sepsis and septic shock, focusing on its potential for more accurate prediction of clinical outcomes.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * hospitalization in the intensive care unit * confirmed diagnosis of sepsis within 24 hours * signed informed consent or a decision by the medical council to include the patient in the study exclusion criteria: * any surgical intervention on the kidneys and/or adrenal glands performed within 28 days prior to the patient's inclusion in the study * patients previously included in this study

Keywords: sepsis septic shock renin lactate procalcitonin
autism research project with non-invasive near-infrared light stimulation

Conditions: Autism Spectrum Disorder

Summary: the investigators have previously shown that the administration of low-level infrared light is a safe and non-invasive procedure which improves cognition and emotion, as well as enhances brain metabolic activity. based on previous studies, the investigators hypothesize that this methodology, called low-level light therapy or photobiomodulation, could be used to improve behavioral symptoms in individuals with autism spectrum disorder (asd).

the gonzalez-lima laboratory at the university of texas at austin will be recruiting participants for a study investigating whether transcranial infrared light stimulation, or tils, is beneficial for people diagnosed with autism spectrum disorder (asd). the molecular target of tils is cytochrome c oxidase, a mitochondrial enzyme which is crucial for oxygen utilization. people with asd show impaired mitochondrial function (siddiqui, elwell, and johnson, 2016), as well as alterations in the prefrontal cortex (amaral, schumann, and nordahl, 2008), which plays a key neurological role in mediating attention, impulse control, and social cognition functions. the lab has previously shown that tils, delivered to the prefrontal cortex, can be used to improve cognitive functions such as attention (barrett and gonzalez-lima, 2013), executive function (blanco, maddox, and gonzalez-lima, 2017), and emotional regulation (zaizar, papini, gonzalez-lima, and telch, 2021). this cognitive enhancement from tils is accompanied by an increase in oxygenation of the prefrontal cortex (holmes, barrett, saucedo, o'connor, liu, and gonzalez-lima, 2019). recently, the beneficial effects of tils on asd symptoms have been safely explored in adults (ceranoglu et al., 2022) and children/adolescents (pallanti et al., 2022). the goal of the study is to recruit children, adolescents, and adults, either asd or non-asd, for a study of the effects of repeated administration of tils on autistic behavior. participants will be asked to give informed consent, complete a series of questionnaires and cognitive tests, and wear a headband to non-invasively monitor brain activity using near-infrared spectroscopy. tils is administered non-invasively with a headband device that uses light-emitting diodes (leds), which are cleared as safe for use in humans by the food and drug administration (fda), but the device has not been approved by the fda for the specific investigational use in this research. the study will train participants (or caregivers) on how to use the led device, then send the participants home to use the led device. the investigators will contact participants once a week to check progress. at the end of the study, participants return for the same assessments, at which time the participants will return the led device.

Eligibility criteria:
inclusion criteria: * age between 4-60 years exclusion criteria: * current pregnancy
effects of serotonin inhibitors on patient-controlled analgesia related nausea and vomiting

Conditions: Agitation

Summary: ed50 of dexmedetomidine for prevention of emergence agitation after tonsillectomy or adenoidectomy in children


Eligibility criteria:
inclusion criteria: * tonsillectomy or adenoidectomy exclusion criteria: * development delay, * cns abnormality

Keywords: agitation, desflurane, children
spinal cord burst stimulation for chronic radicular pain following lumbar spine surgery

Conditions: Back Pain With Radiation; Pain, Postoperative

Summary: spinal cord stimulation (scs) is a widely applied therapy to treat chronic neuropathic pain, and one of the most common indications is persisting radicular neuropathic pain following lumbar spine surgery. in traditional scs therapies, the objective has been to replace the pain sensation with paresthesia. the anticipation is that the electrical current alters pain processing by masking the sensation of pain with a comfortable tingling or paresthesia. although patients mostly cope with paresthesia, a significant proportion reports that the sensation is unpleasant. 'burst' scs utilizes complex programming to deliver high-frequency stimuli. this scs technique seems to provide paresthesia-free stimulation, resulting in better pain relief of low back and leg pain then traditional tonic stimulation. the widespread use of scs has not been backed by solid evidence. the absence of placebo-controlled trials has long been an important point of criticism, but due to the nature of the intervention with sensation of paresthesia, studies with placebo control have so far not been considered possible. when 'burst' scs is used the stimulation is often unnoticed by the patient, allowing comparison with placebo stimulation. the aim of this randomized double-blind sham-controlled crossover trial is to evaluate the efficacy of 'burst' spinal cord stimulation for chronic radicular pain following spine surgery.


Eligibility criteria:
inclusion criteria: * have undergone ≥1 back surgeries and developed chronic radicular pain that has remained refractory to non-surgical treatment for ≥6 months * minimum pain intensity of 5/10 on the leg pain nrs at baseline * successful two-week scs testing period with tonic stimulation (≥2 points reduction in leg pain nrs from baseline). this means patients will experience paresthesia during the scs trial period * mandatory assessment at the multidisciplinary outpatient clinic for back-, neck- and shoulder rehabilitation, st. olavs university hospital exclusion criteria: * coexisting conditions that would increase procedural risk (e.g., sepsis, coagulopathy) * history of laminectomy or posterior fusion at the thoracolumbar junction, where percutaneous electrode end tips are routinely placed. * abnormal pain behavior and/or unresolved psychiatric illness. * unresolved issues of secondary gain or inappropriate medication use.

Keywords: lumbar vertebrae surgery postoperational complications spinal cord stimulation
study of continuous cardiac monitoring to assess atrial fibrillation after cryptogenic stroke

Conditions: Cryptogenic Symptomatic Transient Ischemic Attack; Cryptogenic Ischemic Stroke

Summary: the 2006 american heart association / american stroke association council on stroke guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic recommended that patients with cryptogenic stroke take antithrombotic drugs (i.e. aspirin) in order to prevent a second stroke. when a stroke patient is found to have atrial fibrillation (af), the guidelines recommend oral anticoagulation due to its superior efficacy over aspirin for stroke prevention. physicians can best optimize the use of medicines only if they can precisely and correctly diagnose a patient's af. the purpose of this study is to evaluate the time to first af by 6 months' continuous rhythm monitoring versus control treatment in subjects with a recent cryptogenic stroke or transient ischemic attack (tia) without history of af.


Eligibility criteria:
inclusion criteria: 1. recent cryptogenic symptomatic transient ischemic attack (tia) or cryptogenic ischemic stroke. exclusion criteria: 1. known etiology of tia or stroke. 2. untreated hyperthyroidism. 3. myocardial infarction less than 1 month prior to stroke or tia. 4. coronary bypass grafting less than 1 month prior to stroke or tia. 5. valvular disease requiring immediate surgical intervention. 6. history of af or atrial flutter. 7. patent foramen ovale (pfo) and pfo is or was an indication to start oral anticoagulation (oac). 8. permanent indication for oac at enrollment. 9. permanent contra-indication for oac. 10. included in another clinical trial. 11. life expectancy less than 1 year. 12. pregnant. 13. indicated for implantable pulse generator (ipg), implantable cardioverter-defibrillator (icd), cardiac resynchronization therapy (crt) or an implantable hemodynamic monitoring system. 14. not fit, unable or unwilling to follow the required procedures of the protocol.

Keywords: atrial fibrillation cryptogenic stroke continuous monitoring implantable loop recorder insertable cardiac monitor
the preba study: effect of preoperative weight loss with a 14-day low-calorie diet on surgical procedure and outcomes in patients undergoing rygb surgery

Conditions: Bariatric Surgery; Morbid Obesity

Summary: bariatric guidelines recommend preoperative weight loss of 5% to reduce the risk of surgical complications. however, results in the literature on the improvement of surgical procedure and outcomes are still conflicting. this study aims to evaluate the effect of preoperative weight loss by means of a 14-day low-calorie diet in bariatric patients on operative time, the ease of the roux-en-y gastric bypass (rygb) procedure and long-term weight loss in a real-life experimental setting.


Eligibility criteria:
inclusion criteria: * undergoing primary rygb surgery (meeting all criteria + approval of surgeon) * able to prepare the meal replacements at home exclusion criteria: * undergoing another bariatric procedure than primary rygb. * diabetes mellitus * contraindication for the usage of modifast meal replacements: * allergy or intolerance to any substance in the used meal replacements (soy, milk, gluten, egg, peanuts, nuts and seeds) * veganism * kidney failure (gfr \< 90 ml/min/1.73m2), liver failure or cardiac insufficiency * a heart attack (myocardial infarct) in the past twelve months * cancer * hypokalaemia: serum potassium level \<3.4 mmol/l * phenylketonuria \& porphyria

Keywords: bariatric surgery morbid obesity weight loss diet rygb
smart technology facilitated patient-centered care for patients with pulmonary thromboembolism

Conditions: Venous Thromboembolism; Pulmonary Thromboembolisms; Digital Health

Summary: smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. these technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. they are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention. the objective of this study is to evaluate the impact of mobile venous thromboembolism application (mvtea) based patient-centered management of pulmonary thromboembolism (pte) on the long-term outcome of pte patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with pte.


Eligibility criteria:
inclusion criteria: * inpatients aged ≥18 years; * （2）pte confirmed through imaging examinations, meeting at least one of the following criteria: a.newly diagnosed pte during the current hospitalization; b. prior pte with imaging evidence of residual thrombus. * signed informed consent. exclusion criteria: * previous pte combined with cteph; * mental retardation or a combination of other serious illnesses that make them incapable of living on their own; * inability to use smartphones, computer tablets and other smart devices; * being pregnant or breastfeeding; * have participated in similar trials or are undergoing other clinical trials.

Keywords: venous thromboembolism pulmonary thromboembolisms digital health
brain imaging and pain: analysis of placebo analgesia

Conditions: Brain Imaging of Placebo Analgesia

Summary: this study examines the brain activation associated with placebo pain reduction.

this study is a basic science study of the mechanisms of placebo analgesia in asymptomatic healthy individuals. each participant receives a baseline pain testing session, followed by a conditioning paradigm that results in expectation of pain relief and conditioning. they then undergo functional magnetic resonance imaging during either placebo (conditioned analgesia) or baseline. to examine order effects and habituation, the participants also either undergo a repeated placebo or a repeated baseline. the primary dependent measures in the study are the fmri determined regions of interest, in a network of brain areas associated with pain processing. the anticipated outcome of the study is the alteration of network connectivity between sensory, affective, evaluative areas of the brain associated with placebo. because this is not a traditional clinical trial, there are not traditional efficacy criteria, rather the outcomes are changes in brain function from manipulations of patient expectation and classical conditioning.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * english speaking exclusion criteria: * pain condition * pregnant
effects of green tea on cardiometabolic outcomes

Conditions: Cardiometabolic Syndrome

Summary: cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. it has been postulated that green tea may be beneficial in improving cardiometabolic outcomes. however, to date, no research has explored this using a placebo randomized intervention.


Eligibility criteria:
inclusion criteria: * healthy * between 18 \& 65 years * non-smoker * bmi \< 30 * able to give informed consent exclusion criteria: * pregnancy * diabetes or any other metabolic/ uncontrolled hypertensive conditions * food allergies to quercetin * habitual consumption of quercetin * not regularly taking medication or antioxidant supplements
the thai red cross society prevention of mother-to-child transmission of hiv (trcs pmtct) program

Conditions: HIV-infected Pregnant Women Who Request HAART From the TRCSPMTCT

Summary: to assess the safety and the efficacy of highly active anti-retroviral treatment (haart) for the prevention of mother-to-child transmission of hiv (pmtct)

1. to describe characteristics of hiv-infected pregnant women who request haart from the thai red cross society pmtct (trcs pmtct) program 2. to study adverse pregnancy outcomes among hiv-infected pregnant women who receive haart 3. to study adverse events in infants born to women who receive haart during pregnancy 4. to evaluate risk factors for haart-related toxicities and for perinatal hiv transmission 5. to establish the pilot model of care for hiv-infected pregnant women in middle income country

Eligibility criteria:
inclusion criteria: volunteers meeting all of the following criteria will be considered eligible for enrollment in the study: 1. hiv-infected pregnant women (as defined by the hospital) 2. choose to start haart according to protocol and do not want to receive antiretroviral treatment provided by the other health care systems 3. understand the study and sign informed consent form. persons who cannot read will have the consent form read to them by a study staff and they can give informed consent by using thumb print. 4. availability for follow-up for the planned study duration exclusion criteria: volunteers meeting any of the following criteria will be excluded from the study: 1.persons who have a history of a medical or psychiatric disorder by interview and physical examination according to standard practices, that in the judgment of the treating physician, would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.

Keywords: hiv-infected pregnant women who request haart from the trcspmtct
use of combined prone positioning and high-flow nasal cannula, and non-invasive positive pressure ventilation to prevent intubation in covid-19 infection

Conditions: Prone Positioning; Covid19; Hypoxemic Respiratory Failure; ARDS; Non Invasive Ventilation; High Flow Nasal Cannulla

Summary: this research aims to understand if prone positioning combined with high-flow nasal cannula (hfnc) or non-invasive positive pressure ventilation (nippv) safely reduce the rate of intubation in acute hypoxemic and/or hypercapnic respiratory failure secondary to covid-19 infection.


Eligibility criteria:
inclusion criteria: * patients with confirmed covid19 infection or suspected covid19 infection. * patients requiring hfnc or nippv * patients who are clinically stable and able to tolerate the changes in position that are routinely conducted as part of the standard of care in the medical icu. * patient should be able to provide informed consent to the study. any participant speaking any language will be offered participation. * able to actively participate in assisted manual pronation therapy per nursing assessment. exclusion criteria: contraindication for prone positioning: * intracranial pressure \>30 mm hg or cerebral perfusion pressure \<60 mmhg * massive hemoptysis requiring an immediate surgical or interventional radiology procedure * tracheal surgery or sternotomy during the previous 15 days * serious facial trauma or facial surgery during the previous 15 days * deep venous thrombosis treated for less than 2 days * cardiac pacemaker inserted in the last 2 days * unstable spine, femur, or pelvic fractures * hemodynamic instability or severe cardiac arrhythmia (chronic afib is not a contraindication). mean arterial pressure lower than 60 mm hg, \>1 vasopressor agent or norepinephrine equivalent dose \>0.06 mcg/kg/min * pregnant women * single anterior chest tube with air leaks * burns on more than 20 % of the body surface * delirium or altered mental status increasing fall risk while in prone position. * end-of-life decision before inclusion * subject deprived of freedom, minor, subject under a legal protective measure * unable to actively participate in assisted manual pronation therapy per nursing assessment * lacking capacity to provide informed consent. * individuals with mechanical or vascular disease precluding safe displacement of the head, for example: cervical spinal fusion, limited range of motion, or severe vascular occlusive disease of the head and neck. * body mass index (bmi) greater than 70 kg/m2, or unable to actively participate in assisted manual pronation therapy per nursing assessment at any bmi value.
study of cp-751,871 in combination with carboplatin and paclitaxel in advanced lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: investigate safety, tolerability and pharmacokinetics of cp-751,871 when given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer


Eligibility criteria:
inclusion criteria: * diagnosis of advanced non-small cell lung cancer * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * any prior treatment for non-small cell lung cancer * brain metastases * with diabetes

Keywords: cp-751,871, non-small cell lung cancer, phase 1
icf in takayasu arteritis

Conditions: Takayasu Arteritis

Summary: the aim was to analyze the problem in patients with takayasu arteritis based on the international classification of functioning, disability and health.the sample of our study will consist of individuals between the ages of 18-65 who have been diagnosed with takayasu arteritis by rheumatologists and are followed by pamukkale university rheumatology clinic.


Eligibility criteria:
inclusion criteria:-being between the ages of 18-65 * volunteering to participate in the study * being diagnosed with takayasu arteritis by a rheumatologist exclusion criteria:- having another disease that affects your physical condition * having cognitive impairment that makes it difficult to cooperate * being pregnant * having a neurological disease * having had any surgery in the last year * having another concurrent rheumatic disease